BR0316550A - Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer em um paciente, e para detectar câncer em um paciente - Google Patents

Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer em um paciente, e para detectar câncer em um paciente

Info

Publication number
BR0316550A
BR0316550A BR0316550-7A BR0316550A BR0316550A BR 0316550 A BR0316550 A BR 0316550A BR 0316550 A BR0316550 A BR 0316550A BR 0316550 A BR0316550 A BR 0316550A
Authority
BR
Brazil
Prior art keywords
patient
methods
cancer
treating
compound
Prior art date
Application number
BR0316550-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Amy L Allan
Won Hyung Yoon
Patricia L Gladstone
Robert J Ternansky
Graham Parry
Fernando Donate
Andrew Mazar
Original Assignee
Attenuon Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Attenuon Llc filed Critical Attenuon Llc
Publication of BR0316550A publication Critical patent/BR0316550A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
BR0316550-7A 2002-11-25 2003-11-25 Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer em um paciente, e para detectar câncer em um paciente BR0316550A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42917402P 2002-11-25 2002-11-25
US47553903P 2003-06-02 2003-06-02
PCT/US2003/037895 WO2004063213A2 (en) 2002-11-25 2003-11-25 Peptides which target tumor and endothelial cells, compositions and uses thereof

Publications (1)

Publication Number Publication Date
BR0316550A true BR0316550A (pt) 2005-10-04

Family

ID=32397181

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0316523-0A BR0316523A (pt) 2002-11-25 2003-11-25 Composto, composição farmacêutica e método para tratar ou prevenir câncer em um paciente
BR0316550-7A BR0316550A (pt) 2002-11-25 2003-11-25 Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer em um paciente, e para detectar câncer em um paciente

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR0316523-0A BR0316523A (pt) 2002-11-25 2003-11-25 Composto, composição farmacêutica e método para tratar ou prevenir câncer em um paciente

Country Status (14)

Country Link
US (2) US7517855B2 (enExample)
EP (2) EP1594521A4 (enExample)
JP (2) JP2006514116A (enExample)
KR (2) KR20050096917A (enExample)
AU (2) AU2003297609A1 (enExample)
BR (2) BR0316523A (enExample)
CA (2) CA2506813A1 (enExample)
EA (2) EA200500871A1 (enExample)
HR (2) HRP20050585A2 (enExample)
MX (2) MXPA05005469A (enExample)
NO (2) NO20053112L (enExample)
NZ (2) NZ540889A (enExample)
PL (2) PL377701A1 (enExample)
WO (2) WO2004047771A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0316523A (pt) * 2002-11-25 2005-10-18 Attenuon Llc Composto, composição farmacêutica e método para tratar ou prevenir câncer em um paciente
WO2005114194A1 (en) * 2004-05-21 2005-12-01 Mds Inc. Doing Business Through Its Mds Pharma Services Division Method of quantifying the cell-binding properties of a medical device
US20060078535A1 (en) * 2004-10-13 2006-04-13 The Regents Of The University Of Michigan Anticancer compounds and methods
US20080261892A1 (en) * 2005-02-01 2008-10-23 Ternansky Robert J Acid Addition Salts of Ac-Phscn-Nh2
KR20070100832A (ko) * 2005-02-01 2007-10-11 아테뉴온, 엘엘씨 항혈관신생 ｐｈｓｃｎ 펩티드를 함유하는 조성물
AU2016213759B2 (en) * 2006-11-08 2018-03-29 Chongxi Yu Transdermal delivery systems of peptides and related compounds
AU2006350707A1 (en) 2006-11-08 2008-05-15 Chongxi Yu Transdermal delivery systems of peptides and related compounds
KR20180110187A (ko) 2009-05-08 2018-10-08 테크필즈 바이오켐 코., 엘티디. 펩티드 및 펩티드­관련 화합물의 고침투성 전구약물 조성물
KR101228668B1 (ko) 2010-09-17 2013-01-31 가톨릭대학교 산학협력단 혈관신생 억제 활성을 갖는 펩타이드 및 이의 용도
US9625469B2 (en) 2011-06-23 2017-04-18 Board Of Regents, The University Of Texas System Identifying peptides at the single molecule level
US11435358B2 (en) 2011-06-23 2022-09-06 Board Of Regents, The University Of Texas System Single molecule peptide sequencing
CN102417540A (zh) * 2011-11-21 2012-04-18 中国药科大学 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用
AU2013259166B2 (en) * 2012-05-11 2016-03-10 Theragenics Corporation Biocompatible hydrogel treatments for retinal detachment
US20150305329A1 (en) 2012-06-04 2015-10-29 Michael Fefer Formulations Containing Paraffinic Oil and Anti-Settling Agent
CA2877585C (en) 2013-03-15 2016-04-12 Suncor Energy Inc. Herbicidal compositions
JP5970439B2 (ja) * 2013-09-20 2016-08-17 チョンシー ユー ペプチド及び関連化合物の経皮送達システム
US10545153B2 (en) 2014-09-15 2020-01-28 Board Of Regents, The University Of Texas System Single molecule peptide sequencing
AU2019301750A1 (en) 2018-07-12 2021-01-28 Board Of Regents, The University Of Texas System Molecular neighborhood detection by oligonucleotides
CA3117476A1 (en) 2018-10-05 2020-04-09 Board Of Regents, The University Of Texas System Solid-phase n-terminal peptide capture and release
JP7588289B2 (ja) 2019-02-15 2024-11-22 ニュートリエン・エージー・ソリューションズ・（カナダ）・インコーポレイテッド 植物の健康を増進するプロトポルフィリンｉｘ誘導体及びその使用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4440788A (en) * 1980-05-13 1984-04-03 Mitsubishi Chemical Industries, Limited Cysteine derivatives
WO1981003330A1 (fr) * 1980-05-13 1981-11-26 Mitsubishi Chem Ind Derives de la cysteine et leur production
US4394519A (en) * 1982-01-19 1983-07-19 Research Corporation Amino acid blocking agents
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DE3815221C2 (de) * 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5091176A (en) * 1988-11-02 1992-02-25 W. R. Grace & Co.-Conn. Polymer-modified peptide drugs having enhanced biological and pharmacological activities
US5443816A (en) 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
US5229366A (en) * 1990-10-23 1993-07-20 Fuji Photo Film Co., Ltd. Peptide-containing polyethylene glycol derivatives and application thereof
US5149801A (en) * 1990-11-21 1992-09-22 The Regents Of The University Of California Boronated porphyrin compounds
US5561220A (en) 1991-02-08 1996-10-01 Diatech, Inc. Technetium-99m labeled peptides for imaging inflammation
US5698155A (en) * 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5556609A (en) 1992-02-20 1996-09-17 Rhomed Incorporated YIGSR peptide radiopharmaceutical applications
US5608110A (en) 1993-06-15 1997-03-04 Bracco International B.V. Heteroatom-bearing ligands and metal complexes thereof
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
ATE218381T1 (de) 1995-03-14 2002-06-15 Siemens Ag Ultraschall-zerstäuber mit abnehmbarer präzisionsdosiereinheit
US5950619A (en) * 1995-03-14 1999-09-14 Siemens Aktiengesellschaft Ultrasonic atomizer device with removable precision dosating unit
US5618513A (en) * 1995-06-07 1997-04-08 Mallinckrodt Medical, Inc. Method for preparing radiolabeled peptides
MY147327A (en) 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
JP2001501600A (ja) * 1996-09-10 2001-02-06 ザ バーナム インスティテュート 腫瘍ホーミング分子、それに由来する結合体、およびその使用方法
US6331409B1 (en) * 1996-11-21 2001-12-18 The Regents Of The University Of Michigan Methods and compositions for wound healing
US6001965A (en) * 1996-11-21 1999-12-14 The Regents Of The University Of Michigan Anticancer compounds and methods
US6025150A (en) * 1996-11-21 2000-02-15 The Regents Of The University Of Michigan Methods and compositions for wound healing
US6011170A (en) * 1997-01-14 2000-01-04 Kaneka Corporation Process for producing of cysteine derivatives
US5994309A (en) 1997-07-25 1999-11-30 Angstrom Pharmaceuticals, Inc. Anti-invasive and anti-angiogenic compositions and methods
WO1999013329A1 (en) * 1997-09-10 1999-03-18 The Burnham Institute Methods of identifying molecules that home to angiogenic vasculature in tumors
NZ504021A (en) * 1997-10-17 2003-04-29 Systemic Pulmonary Delivery Lt Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
EP1159292A2 (en) * 1998-08-14 2001-12-05 Administrators of The Tulane Educational Fund Compounds having growth hormone releasing activity
CA2435320C (en) 2001-01-18 2008-06-03 The Regents Of The University Of Michigan Compositions and methods for the use of fibronectin fragments in the diagnosis of cancer
BR0316523A (pt) * 2002-11-25 2005-10-18 Attenuon Llc Composto, composição farmacêutica e método para tratar ou prevenir câncer em um paciente

Also Published As

Publication number Publication date
EP1594521A2 (en) 2005-11-16
AU2003298726A1 (en) 2004-08-10
EP1569678A2 (en) 2005-09-07
EA200500871A1 (ru) 2006-04-28
NO20053112L (no) 2005-08-05
EA200500870A1 (ru) 2006-04-28
AU2003297609A1 (en) 2004-06-18
MXPA05005469A (es) 2005-09-08
JP2006514116A (ja) 2006-04-27
KR20050097494A (ko) 2005-10-07
NZ540363A (en) 2007-11-30
CA2507045A1 (en) 2004-06-10
CA2506813A1 (en) 2004-07-29
JP2006515866A (ja) 2006-06-08
EP1594521A4 (en) 2008-01-09
NZ540889A (en) 2008-09-26
PL377701A1 (pl) 2006-02-06
NO20053111D0 (no) 2005-06-24
US7517855B2 (en) 2009-04-14
US20040162239A1 (en) 2004-08-19
WO2004063213A2 (en) 2004-07-29
MXPA05005545A (es) 2005-10-18
KR20050096917A (ko) 2005-10-06
WO2004063213A3 (en) 2005-03-03
HRP20050585A2 (en) 2006-02-28
PL377763A1 (pl) 2006-02-20
US20050020810A1 (en) 2005-01-27
NO20053111L (no) 2005-08-24
WO2004047771A2 (en) 2004-06-10
NO20053112D0 (no) 2005-06-24
BR0316523A (pt) 2005-10-18
WO2004047771A3 (en) 2005-09-15
EP1569678A4 (en) 2008-01-02
HRP20050584A2 (hr) 2006-04-30

Similar Documents

Publication Publication Date Title
BR0316550A (pt) Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer em um paciente, e para detectar câncer em um paciente
BRPI0416656A (pt) compostos de pirrolopirimidina úteis no tratamento do cáncer
BRPI0213223B8 (pt) polipeptídeo, dímero ou multímero, polinucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica, e, uso de uma composição
RU2008130963A (ru) Лечение метастатического рака молочной железы
BR0112038A (pt) Triazolopirimidinas substituìdas como agentes anticâncer
PE20021080A1 (es) Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer
ATE364698T1 (de) Neues, physiologisch aktives peptid und dessen verwendung
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
MY162319A (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
EA201170139A1 (ru) 5-фенилизоксазол-3-карбоксамиды с противоопухолевыми активностями, модулирующие hsp90
NO20061319L (no) 5-arylpyrimidiner som anticancer legemidler
ATE536745T1 (de) Zusammensetzung mit arazym zur prävention und behandlung von krebs
EA200700976A1 (ru) Соединения в виде молекул-конъюгатов, обладающих повышенной активностью в отношении включения клеткой
JP2010508242A5 (enExample)
NO20055209D0 (no) Peptabody for cancerbehandling
MX349364B (es) Variante de alfa-1 antitripsina novedosa, método de preparación de la misma, y uso de la misma.
EP2717869B1 (en) Methods of treatment using a bcat1 inhibitor
Yin et al. Inhibition of tumor metastasis in vivo by combination of paclitaxel and hyaluronic acid
Zhang et al. Human hemokinin-1 promotes migration of melanoma cells and increases MMP-2 and MT1-MMP expression by activating tumor cell NK1 receptors
BRPI0408238A (pt) anticorpo, método de detectar cáncer, conjunto para detecção de cáncer, e, composição farmacêutica para tratar cáncer
DE602005007471D1 (de) Satraplatin zur behandlung von resistenten oder refrkatären tumoren
BR0317052A (pt) Composto, métodos para tratar câncer ou doença neoplástica e uma infecção fúngica, para inibir o desenvolvimento de uma célula cancerosa ou célula neoplástica e de um fungo e para induzir a citotoxicidade em uma célula cancerosa ou célula neoplástica, e, composição
EA200601471A1 (ru) Ингибиторы клеточной пролиферации клеток (варианты), фармацевтическая композиция на их основе, способ уничтожения раковых клеток (варианты) и способ лечения и профилактики злокачественных состояний (варианты)
Donenko et al. Quantitative regulation of melanoma growth in the host by tumor-specific serpins in blood serum is a main reason for inefficient tumor treatment
RU2022118334A (ru) Модуляторы активности комплемента

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010.